Speed Vs Cost in Peptides: Choosing the Right Path to Market

Executive Summary

Getting a peptide from idea → clinic → market is a trade‑off  between time‑to‑data and unit economics. In practice you’re choosing  among SPPS (solid‑phase), LPPS (solution‑phase), or a hybrid (SPPS  fragments + solution ligation). This review frames that choice with  current industry facts and literature and adds basics plus process flows  for each route.

Peptide Basics (fast primer)

• Definition: short polymers of amino acids (typically  2–50 aa), defined by primary sequence; above ~50 aa often termed small  proteins.

• Key attributes: sequence, charge, hydrophobicity,  stereochemistry; common motifs include disulfides, β‑branched residues,  and PTM handles.

• Typical dosage forms: sterile solutions or  lyophilized powders for injection; growing interest in long‑acting  depots and transdermals.

• Common liabilities: oxidation  (Met/Trp), deamidation (Asn/Gln), isomerization (Asp), aggregation;  counter‑ion choice (TFA vs acetate) impacts stability and residuals.

• Analytics: HPLC/UPLC with MS, chiral or mixed‑mode as needed; elemental impurities and residual solvents per ICH.

What Drives the Decision

1) Sequence & chemistry risk.

SPPS remains the workhorse for complex or longer sequences  (β‑branched, hydrophobic runs, PTMs) thanks to modular cycles, on‑resin  tactics (pseudoprolines, backbone protection), and process  intensification (microwave, double coupling). Key side reactions include  aspartimide, racemization, DKP, and oxidation—each eroding crude purity  and time.

2) Purification load (the hidden bottleneck).

As chain length rises, crude purity often drops, driving heavy  preparative HPLC and significant acetonitrile/solvent use;  lyophilization is the next choke point. These two operations dominate  schedule and solvent footprint.

3) Scale & unit economics.

LPPS wins when fragments or protected intermediates crystallize  cleanly; purity is banked stepwise and HPLC is offloaded. Modern  practice often goes hybrid: make shorter segments (SPPS or LPPS), then  ligate (e.g., NCL) to reach size while controlling cost.

Route selection should be revisited at defined development milestones rather than fixed early.

4) Sustainability & EHS realities.

SPPS consumes large volumes of DMF/NMP/DCM and strong bases;  greener solvent systems (NBP, binary green mixes) are emerging but  remain sequence/resin dependent. LPPS shifts the burden toward bulk  solvent handling and abatement (RTO/carbon) and can lower overall PMI if  HPLC is reduced.

Process Flow – SPPS (Fmoc/tBu typical)

1. Resin Selection & Preparation

• Select appropriate resin based on target peptide and C-terminal functionality (e.g., Wang, Rink Amide, 2-CTC).

• Swell resin in DMF (or DCM/DMF mix) for adequate solvation.

• Confirm resin loading (mmol/g) and batch traceability.

2. Fmoc Deprotection (Initial or Cycle Step)

• Treat resin with 20–25% piperidine in DMF (single or double treatment).

• Removes Fmoc protecting group, exposing free amine.

• Wash thoroughly with DMF to remove piperidine and by-products.

• Optional Kaiser or Chloranil test to confirm free amine.

3. Amino Acid Activation

• Fmoc-protected amino acid dissolved in DMF.

• Activate using coupling reagents (e.g., HBTU, HATU, PyBOP) with base (DIPEA or NMM).

• Maintain controlled molar excess (typically 3–5 eq).

4. Coupling Reaction

• Add activated amino acid to resin.

• React for defined time (30–90 min, depends on sequence).

• Agitation via shaker or reactor rotation.

• Monitor coupling efficiency (Kaiser test).

• Repeat coupling if incomplete (double coupling or capping).

5. Capping (Optional but Recommended)

• Cap unreacted amines using acetic anhydride / DIPEA.

• Prevents deletion sequences and improves purity.

6. Wash Cycle

• Sequential washes with DMF (sometimes DCM/IPA) to remove excess reagents.

• Critical for preventing carryover and side reactions.

7. Repeat Deprotection–Coupling Cycles

• Steps 2–6 repeated iteratively until full peptide sequence is assembled (C-terminus → N-terminus direction).

8. Final Fmoc Deprotection

• Remove terminal Fmoc group using piperidine/DMF.

• Wash resin thoroughly.

9. Side-Chain Deprotection & Cleavage from Resin

• Treat resin with TFA-based cleavage cocktail (e.g., TFA/TIS/water/EDT depending on sequence).

• Simultaneous cleavage from resin and removal of tBu-based side-chain protections.

• Typical reaction time: 1–3 hours at RT.

10. Peptide Precipitation & Recovery

• Filter resin, collect TFA solution.

• Precipitate peptide using cold ether or MTBE.

• Centrifuge and wash precipitate to remove scavengers.

11. Crude Peptide Drying

• Dry under nitrogen or vacuum.

• Obtain crude peptide solid.

12. Purification (Downstream, if required)

• Preparative RP-HPLC (C18).

• Fraction collection based on UV/MS.

• Pool acceptable fractions.

13. Final Drying

• Lyophilization to obtain final peptide as powder.

14. Quality Control

• Identity: LC-MS / HRMS

• Purity: Analytical HPLC

• Water content (KF), residual solvents, counter-ion if needed.

Process Flow – LPPS (solution‑phase)

1. Building Block / Fragment Strategy

• Define synthesis approach:

-Stepwise amino acid coupling, or

-Fragment condensation (di-, tri-, or Oligo-peptides).

• Select appropriate N-terminal and Side-chain protecting groups:

-N-terminus: Boc or Fmoc (Boc more common historically in LPPS)

-Side chains: Benzyl, tBu, Z, etc.

• Verify raw material quality (purity, chirality, water content).

2. N-Terminal Protection (If Not Pre-Protected)

• Protect free amino group using suitable reagent (e.g., Boc anhydride).

• Reaction performed in organic solvent (DCM, THF, or similar).

• Aqueous work-up and phase separation.

• Isolation of protected amino acid by crystallization or extraction.

3. Carboxyl Group Activation

• Activate C-terminal carboxyl group of first amino acid or fragment.

• Common activation systems:

-Acid chlorides

-Mixed anhydrides

-Carbodiimides (DCC, EDC) ± additives (HOBt, HOAt)

• Control temperature to minimize racemization.

4. Coupling Reaction (Solution Phase)

• Add activated acid to amine-protected amino acid or fragment.

• Reaction carried out under inert atmosphere if required.

• Monitor reaction completion by TLC, HPLC, or LC-MS.

• Typical reaction time: several hours to overnight.

5. Reaction Quench and Work-Up

• Quench reaction to destroy excess coupling reagent.

• Aqueous washes to remove:

-Urea by-products

-Excess acids/bases

• Phase separation and solvent drying.

6. Intermediate Isolation

• Isolate coupled peptide intermediate by:

-Crystallization (preferred for scale)

-Precipitation

-Solvent evaporation followed by trituration

• Dry isolated intermediate.

• Perform in-process testing (purity, identity).

  
  

7. N-Terminal Deprotection

• Remove N-terminal protecting group:

-Boc: acidolysis (e.g., TFA or HCl in dioxane)

-Fmoc: base treatment (e.g., piperidine)

• Neutralization and aqueous work-up.

• Isolation of deprotected intermediate.

  
  

8. Iterative Chain Elongation

• Repeat activation → coupling → work-up → isolation → deprotection

• Each cycle adds one amino acid or fragment.

• Careful control needed to prevent:

-Racemization

-Side reactions

-Impurity accumulation

9. Final Deprotection (Side Chains)

• Remove side-chain protecting groups using appropriate conditions:

-Hydrogenation (for benzyl groups)

-Acidic cleavage (for tBu-based protections)

• Reaction monitored for completeness.

10. Crude Peptide Isolation

• Concentrate reaction mixture.

• Precipitate peptide or isolate via crystallization.

• Filter and wash to remove residual reagents.

11. Purification (If Required)

• Purification methods:

-Crystallization / re-crystallization (preferred at scale)

-Preparative chromatography (limited use at large scale)

• Aim to meet target purity with minimal solvent burden.

12. Final Drying

• Vacuum drying or lyophilization.

• Control residual solvent and moisture levels.

13. Quality Control

• Identity: LC-MS

• Purity: HPLC

• Chiral purity (if required)

• Residual solvents, water content

• Counter-ion confirmation

Process Flow – Hybrid Peptide Synthesis (SPPS Fragments with Ligation)

1.Fragment Design

The full peptide sequence is divided into shorter fragments at  ligation-compatible junctions (e.g., cysteine or auxiliary-enabled  positions) to enable efficient downstream coupling.

2.Fragment Manufacture

Individual peptide segments are synthesized using SPPS (or LPPS  where appropriate). Fragments intended for ligation are optionally  converted to reactive thioester forms suitable for native chemical  ligation (NCL).

3.Fragment Ligation

Peptide fragments are coupled using chemo selective ligation  chemistry (e.g., native chemical ligation) in aqueous buffer systems.  Reaction progress and conversion are monitored to confirm completion.

4.Post-Ligation Processing

Following ligation, optional post-ligation modifications are  performed as required, including desulfurization (e.g., Cys-to-Ala  conversion when auxiliaries are used), disulfide bond formation, and  intermediate polishing steps.

5.Purification and Isolation

The ligated peptide is purified, typically with reduced burden  compared to full-length SPPS of long sequences. Final processing  includes lyophilization and salt form adjustment, as applicable.

Key Control Points:

Fragment purity, ligation efficiency and conversion, by-product profile, and final purification load.

A Pragmatic Approach:

1) Start with SPPS when speed is existential.

If tox or FIH speed matters, SPPS shortens development loops. Lock  in DIC/Oxyma (or equivalent), sequence‑specific protecting strategies,  and run small resin/solvent screens before scale.

2) Plan for a hybrid route before Phase III.

Evaluate fragmentation + ligation early. Native Chemical Ligation  (NCL) and modern variants allow joining fully deprotected fragments in  water, expanding practical length while maintaining native backbones;  the approach is cost‑effective once volumes rise.

3) Treat purification & lyo as first‑class assets.

HPLC + lyophilization drive schedule and solvent footprint.  Capacity planning (column sizing, cycles/day, ACN recycling) and  alternative purification (IEX, mixed‑mode, crystallizations of  intermediates or salts) often move the business case more than squeezing  2–3% yield in coupling.

4) De‑risk sustainability early.

Peer‑reviewed work shows viable DMF replacements (NBP; binary  green systems) with comparable outcomes in select cases; still, run  comparative DoEs—don’t assume drop‑in parity. Capture PMI routinely; it  correlates with both compliance and cash burn on multi‑kg campaigns.

A Simple Decision Lens

• Difficult recurring unit or >30–40 aa → SPPS (or hybrid) to reduce chemistry risk.

• If fragments crystallize → LPPS/hybrid lowers HPLC/lyo burden and COGS.

• Timeline critical → SPPS to clinic; switch to hybrid when forecasts justify.

• Sustainability constraints (DMF/NMP limits) → pilot greener SPPS or use LPPS with abatement.

Current Industry Trends

• Greener SPPS is moving from papers to plants (NBP and optimized binary systems).

• NCL keeps expanding what is practical to ligate, making hybrid routes attractive for launch scale.

• PMI/COGS transparency: HPLC solvent and lyo hours dominate PMI on long SPPS-only chains; hybrid designs ease that load.

Bottom Line

SPPS to clinic, hybrid to market is now common: capture speed  early, then pull cost and solvent burden down with fragment  condensation/ligation as volumes grow. Don’t over‑optimize coupling  minutiae while ignoring HPLC/lyo—the latter usually sets both cash and  calendar.

Selected References

[1] Isidro‑Llobet A., et al. Sustainability challenges in peptide synthesis and purification. J. Org. Chem., 2019.

[2] Pennington M.W., et al. Commercial manufacturing of cGMP peptide APIs. Reaction Chemistry & Engineering, 2021.

[3] Palasek S.A., et al. Limiting racemization and aspartimide formation in microwave‑assisted SPPS. J. Pept. Sci., 2007.

[4] Neumann K., et al. Prevention of aspartimide formation during peptide synthesis. Org. Process Res. Dev., 2020.

[5] Martin V., et al. Greening the synthesis of peptide therapeutics. Green Chemistry, 2020.

[6] Ferrazzano L., et al. Sustainability in peptide chemistry. Green Chemistry, 2022.

[7] Kumar A., et al. N‑Butylpyrrolidinone as a greener solvent for SPPS. ChemSusChem, 2020.

[8] Jadhav S., et al. Replacing DMF in SPPS with green binary mixtures. Green Chemistry, 2021.

[9] Mant C.T., et al. HPLC analysis and purification of peptides. Methods in Molecular Biology, 2007.

[10] Tam J.P., et al. Native chemical ligation and modern variants. Chemical Reviews, 2019.

[11] Brik A., et al. Enhancing native chemical ligation for challenging protein syntheses. Chem. Soc. Rev., 2021.

[12] PMI benchmarking for peptide routes. Green Process Synth., 2023.

Appendix-1: Acronym Glossary: